Continuous Glucose Monitoring Systems Market is
anticipated to hit $4,921
million by 2024 from $758 million in 2017, at a CAGR of 22.9%
from 2016-2024.
Market growth has been amplified in
several ways due to the benefits of CGMS over POC glucometers, increased
incidence of diabetes cases, and advanced technological advances in the medical
field. On the other hand, certain adverse effects of the system and some strict
guidelines by the government have limited some growth by chance. However, the
high adoption rate of CGMS in home healthcare, increased product awareness, and
an increasing number of undiagnosed patients have created multiple
opportunities in this segment.
Industry Key Players
The report offers quite a few key
market players including
·
Dexcom Inc.
·
Abbott Laboratories
·
Echo Therapeutics Inc.
·
Insulet Corporation
·
F. Hoffmann-La Roche Ltd.
·
Senseonics Holdings
·
Menarini Diagnostics
·
GlySens Incorporated
·
Johnson & Johnson and Medtronic plc Inc.
The report offers a thorough
analysis of market dynamics, top investment pockets, market definition &
scope, key market trends and market size. Based on components, the sensors
segment is remains to be the largest sector, airing a CAGR of 22.9% during the
forecast period. The expected technological advances has rocketed the growth
and made the segment hold major market share. By end user, diagnostic centers/clinics
dominate the global market, garnering a CAGR of 22.1% throughout the forecast
period. Cutting-edge CGMS programs in diagnostics clinics have spurred the
growth. Simultaneously, home health care has been cited as the fastest growing
market, registering a CAGR of 30.9% from 2016-2024. This is due to the fact
that continuous glucose monitoring systems are easier to use and are less
painful.
No comments:
Post a Comment